CERT Earnings Date: Nov 5, 2026 (Estimated) — Certara, Inc.
NASDAQ · Healthcare · Health Information Services
Updated
When is CERT's next earnings date?
Certara, Inc. (CERT) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.09 on revenue of $92.0M.
How did CERT do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Certara, Inc. posted EPS of $0.08 versus the $0.09 estimate, a miss of 11.1%. Revenue was $93.3M against a $98.1M estimate. The stock's 1-day post-earnings move was -4.6%.
How much does CERT stock move after earnings?
CERT beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 11.2% (up or down) in the day after earnings.
About Certara, Inc.
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | 0.09 | 0.08 | -11.11% | $93.3M | ❌ Miss | -4.65% | -1.34% | -0.98% |
| 2026-05-11 | Q1 2026 | 0.10 | 0.09 | -10.00% | $106.9M | ❌ Miss | -18.70% | -29.00% | -17.91% |
| 2026-02-26 | Q4 2025 | 0.09 | 0.09 | +0.00% | $103.6M | ➖ Inline | +3.19% | +11.53% | -6.83% |
| 2025-11-06 | Q3 2025 | 0.09 | 0.14 | +55.56% | $104.6M | ✅ Beat | -23.07% | -25.38% | -19.34% |
| 2025-08-06 | Q2 2025 | 0.08 | 0.07 | -12.50% | $104.6M | ❌ Miss | +18.15% | +17.21% | +10.39% |
| 2025-02-26 | Q4 2024 | 0.13 | 0.15 | +15.38% | $100.4M | ✅ Beat | +0.57% | -3.41% | -17.92% |
| 2024-08-06 | Q2 2024 | 0.10 | 0.07 | -30.00% | $93.3M | ❌ Miss | -13.59% | -17.44% | -24.01% |
| 2024-05-07 | Q1 2024 | 0.10 | 0.10 | +0.00% | $96.7M | ➖ Inline | -7.42% | -7.02% | -2.66% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q2 FY26 · $93.3M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Americas | 66.6% | $62.1M | -14.9% | $69.9M | $72.0M | $73.0M | $74.0M |
| EMEA | 22.2% | $20.7M | -11.4% | $18.1M | $25.8M | $23.4M | $21.9M |
| Asia Pacific | 11.2% | $10.5M | +27.4% | $6.8M | $8.3M | $8.2M | $8.7M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.